CN106119244A - The test kit of detection Kui sulfur flat medication effect based on rs6269 and using method thereof - Google Patents

The test kit of detection Kui sulfur flat medication effect based on rs6269 and using method thereof Download PDF

Info

Publication number
CN106119244A
CN106119244A CN201610298336.XA CN201610298336A CN106119244A CN 106119244 A CN106119244 A CN 106119244A CN 201610298336 A CN201610298336 A CN 201610298336A CN 106119244 A CN106119244 A CN 106119244A
Authority
CN
China
Prior art keywords
seq
test kit
nucleotide
sequencing
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610298336.XA
Other languages
Chinese (zh)
Inventor
秦胜营
徐青青
周伟
沈陆
欧阳君
贺林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiaotong University
Original Assignee
Shanghai Jiaotong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiaotong University filed Critical Shanghai Jiaotong University
Priority to CN201610298336.XA priority Critical patent/CN106119244A/en
Publication of CN106119244A publication Critical patent/CN106119244A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides test kit and the using method thereof of a kind of detection Kui sulfur flat medication effect based on rs6269, a kind of separates nucleic acid, a kind of allele specific nucleic acid primer and the detection method of COMT gene rs6269 single nucleotide polymorphism；Determine the nucleotide of the 20689th of sequence shown in SEQ ID NO:6, detect whether this site exists single nucleotide polymorphism.The method of described detection includes: DNA sequencing, sequencing by hybridization, enzymatic mispairing cutting, heteroduple analysis, dot blot, oligonucleotide arrays, Mini sequencing, Taqman technology, molecular beacon or denaturing high-performance liquid chromatography.

Description

The test kit of detection Kui sulfur flat medication effect based on rs6269 and using method thereof
Technical field
The present invention relates to the nucleic acid in gene technology field and primer thereof and detection method, be a kind of based on rs6269 The test kit of detection Kui sulfur flat medication effect and using method thereof, be more particularly a kind of separation nucleic acid, a kind of allele Specific nucleic acid primer and the detection method of COMT gene rs6269 single nucleotide polymorphism.
Background technology
Kui sulfur puts down (Quetiapine) chemical entitled 11-{4-[2-(2-(hydroxy ethoxy) ethyl-1-piperazine] } dibenzo [b, f] [Isosorbide-5-Nitrae] sulfur azepine1/2 fumarate, molecular formula C21H25N302S 1/2C4H404.Quetiapine is a kind of novel Psychosis, all has interaction to the various neurotransmitters receptor such as dopamine, 5-hydroxy tryptamine.Clinical research shows that Kui sulfur is put down Not only effective to the schizophrenia positive symptom, negative symptoms is also had certain effect.Can also alleviate and have with schizophrenia The affective symptom closed such as depressed, anxiety and cognitive defect symptom.Common adverse reactions is dizzy, drowsiness, orthostatic hypotension, the heart Throb with fear, xerostomia, inappetence and constipation.Also body weight can be caused to increase, stomachache, silent ALP increases and blood T-CHOL and sweet Oil three esters increase.Although compared with classical psychosis, although the adverse effect caused by Quetiapine is less, toleration Preferably, but once generation can cause the major injury of nervous system, liver and gall, digestive system and cardiovascular system.Research Showing, drug effect and drug side effect that Kui sulfur is flat have obvious individual variation, and reason is that its metabolism is by inherited genetic factors and environment The impact of factor, but inherited genetic factors is topmost reason.Therefore the molecular marker that the more metabolism flat to Kui sulfur of exploitation is relevant Thing thus patient is realized individualized treatment and is necessary.
COMT (Catechol-O-methyltransferase) gene is positioned on No. 22 chromosome q11.21 of the mankind, Different cells is translated into the albumen of different length.In the neurocyte of brain, COMT gene expression is that film combines Catechol O-methyltransferase albumen；Catechol O-methyltransferase albumen in brain is mainly distributed on prefrontal cortex District, it may ensure that neurotransmitter such as dopamine etc. are in a stable level.The organs such as liver, kidney and blood are expressed as The catechol O-methyltransferase albumen of solubility, it can be catalyzed methyl and transfer to catecholamine from S-adenosylmethionine On, this type of material includes neurotransmitter dopamine, epinephrine, norepinephrine etc..COMT gene treats high blood in metabolism Pressure, asthma, the catechol medicine aspect of Parkinson disease play an important role.Owing to Kui sulfur is flat and dopamine, 5-hydroxy tryptamine All having interaction etc. various neurotransmitters receptor, therefore finding the flat metabolism of Kui sulfur is existing with the relation of COMT gene pleiomorphism Technology urgent need to solve the problem.
Retrieval to existing document, the COMT gene SNP rs6269 finding no the present invention is the flat molecular marked compound of Kui sulfur Relevant report.
Summary of the invention
For deficiency of the prior art, it is an object of the invention to provide a kind of detection Kui flat medication of sulfur based on rs6269 The test kit of effect and using method thereof, relate to a kind of separation nucleic acid, a kind of allele specific nucleic acid primer simultaneously.This Invent have found COMT gene SNP rs6269 by association analysis can be as the flat molecular marked compound of Kui sulfur.
It is an object of the invention to be achieved through the following technical solutions:
First aspect, the present invention provides the nucleotide containing mononucleotide polymorphism site of a kind of separation, described nucleotide Sequence as shown in SEQ ID NO:6, described mononucleotide polymorphism site is positioned at the 20689th, and rs6269 is A → G.
Second aspect, the present invention provides a kind of described nucleotide in the test kit of preparation detection Kui sulfur flat medication effect Purposes.
The third aspect, the present invention provides the nucleotide of a kind of separation, the sequence of described nucleotide such as SEQ ID NO:6 institute Show, and the 20689th is A.
Fourth aspect, the present invention provides a kind of test kit detecting Kui sulfur flat medication effect, and described test kit includes: according to The primer pair of the upstream and downstream design of the 20689th of sequence as shown in SEQ ID NO:6.
Preferably, described primer pair: shown in SEQ ID No.3, SEQ ID No.4, SEQ ID No.5.
5th aspect, the present invention provides the non-diagnostic purpose using method of a kind of described test kit, comprises the steps:
Step one, extracts sample DNA；
Step 2, utilizes described primer to expand, obtains amplified production；
Step 3, detects the single nucleotide polymorphism position whether existed in described amplified production as shown in SEQ ID NO:6 Point rs6269.
Preferably, in step 3, the method for described detection includes: DNA sequencing, sequencing by hybridization, enzymatic mispairing cutting, allos RNA polymerase, dot blot, oligonucleotide arrays, Mini-sequencing, Taqman technology, molecular beacon or denaturing high-performance liquid Phase chromatography.
Preferably, in step 2, the actual conditions of described amplification is as follows: reaction system is 20 μ l, wherein contains:
100μmol·L-1DNTPs, 50mmol L-1KCL, 10mmol L-1Tris-HCL (pH8.3), 1.5mmol L- 1MgCl2, 0.5U Taq archaeal dna polymerase, 20-50ng template DNA, 0.5 μ l10pM SEQ ID No.3,0.5 μ l10pM SEQ ID No.4, distilled water complements to 20ul；
PCR reaction condition: 95 DEG C of 2mins；30×(94℃30s；58 DEG C of 30s, 72 DEG C of 30s) 72 DEG C of 5mins.
6th aspect, the present invention provides the primer pair of a kind of SNP site for detecting described nucleotide, described primer Right: shown in SEQ ID No.3, SEQ ID No.4, SEQ ID No.5.
Compared with prior art, the present invention possesses following advantageous effect: the present invention is for studying COMT gene pleiomorphism and facing The relation of bed drug safety is laid a good foundation, and provides fundamental basis for clinical application individuation, is also based on drug gene simultaneously The new drug development that group scientific principle is read provides and instructs foundation.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is expanded on further.Should be understood that these embodiments are merely to illustrate the present invention Rather than restriction the scope of the present invention.The experimental technique of unreceipted actual conditions in the following example, usual more solito condition, The molecular cloning of such as Sambrook et al.: laboratory manual (New York:Cold Spring Harbor Laboratory Press, 1989) condition described in, or according to the condition proposed by manufacturer.Described " isolated or purification " is Refer in genomic DNA level, utilize primer to expanding the gene order of each pleomorphism site and utilizing purification kit Amplified production is purified.
The sample that the present invention uses is from 995 schizophrenics of Shanghai Mental Health Center, age 18-60 Year.All participants are agreed to signature by family members on formal Informed Consent Form.
On the basis of above-mentioned, the present invention uses fragment length difference ApoE gene (FLDAS-PCR) typing Rs6269SNP site and the frequency distribution situation thereof of COMT gene are detected by technology.Have discovered that COMT gene The 20689th A → G polymorphism of the rs6269 of (SEQ ID NO:6).
Concrete grammar is as follows: design primer at COMT gene SNP rs6269 mutational site, and 3 ' ends of primer are by mispairing The different designs of base two set primers, wild type forward primer introduces base mispairing, 5 ' at 3 ' end the 3rd bit bases End introduces 5 base mispairings, and saltant type forward primer introduces a base mispairing at 3 ' end the 4th bit bases；Downstream primer is Universal primer.Saltant type product 5bp more than wild type is found by three pairs of primer amplification purpose fragments and after running glue detection, thus real Existing SNP gene type.
The cDNA sequence of COMT gene rs6269 is listed in SEQ ID NO:1, and its coded aminoacid sequence is listed in SEQ ID NO:2.The genome sequence of No. six intron of COMT gene can obtain from GenBank.
The present invention has substantial amounts of analytical technology to can be used for detecting whether site described in No. six intron of COMT gene deposits In single nucleotide polymorphism.These technology include (but being not limited to): DNA sequencing, sequencing by hybridization；Enzymatic mispairing cutting, allos RNA polymerase, dot blot, oligonucleotide arrays (DNA chip), Mini-sequencing, Taqman technology, molecular beacon etc., Denaturing high-performance liquid chromatography (DHPLC).On the other hand, the detection method of the present invention is used for assessing individual COMT gene SNP Rs6269 polymorphism and the relation of the flat metabolism of Kui sulfur.Test sample for the present invention is not particularly limited, for detection SNP Speech, can be DNA or mRNA extracted from the sample such as blood, tissue.For No. six intron activity of COMT gene Speech, can any sample containing COMT gene SNP rs6269, such as blood etc..
The present invention is that in research population of China, the relation of COMT gene pleiomorphism and clinical drug safety is laid a good foundation, for Clinical application individuation is provided fundamental basis, and the most also provides guidance to depend on for new drug development based on pharmacogenomics theory According to.
More specifically, the present invention realizes in the following way:
The present invention provides separation and the typing of a kind of nucleic acid:
Design of primers:
Use Primer 5.0 software, with GenBank data base's COMT gene (ID:1312, as shown in SEQ ID No.6) SNP rs6269 adnexa sequence is stencil design pair of primers, Invitrogen company synthesize.
Primer information:
The DNA sequence primer information in amplification COMT gene SNP rs6269 site:
Wild type rs6269-A (SEQ ID No.3): 5 '-gacgaACCATCGCCCCCTTGTGaTT-3 '
Saltant type rs6269-G (SEQ ID No.4): 5 '-ACCATCGCCCCCTTGTcTTC-3 '
Universal rs6269-R (SEQ ID No.5): 5 '-GCACCAGAGGGCACGAGAAGGC-3 '
PCR amplification condition: (the every reagent of system is provided by ABI company in addition to DNA)
100μmol·L-1DNTPs, 50mmol L-1KCL, 10mmol L-1Tris-HCL (pH8.3), 1.5mmol L- 1MgCl2, 0.5U Taq archaeal dna polymerase, 20-50ng template DNA, 0.5 μ l10pM SEQ ID No.3,0.5 μ l10pM SEQ ID No.4, distilled water complements to 20ul；
PCR reaction condition: 95 DEG C of 2mins；30×(94℃30s；58 DEG C of 30s, 72 DEG C of 30s) 72 DEG C of 5mins.
After above-mentioned PCR has reacted, amplified production is silver staining after native polyacrylamide gel electrophoresis, Ke Yifa Existing COMT gene SNP rs6269 wild type (genotype is A) amplified production is more than saltant type (genotype is G) 5bp, therefore Genotype be homozygous individual amplified production be single band, heterozygous individual is double bands.COMT is found through FLDAS-PCR typing Gene SNP rs6269 has polymorphism (i.e. the 20689th A → G).Association analysis finds the G gene of COMT gene SNP rs6269 Having significant individual variation, P value before and after type and A genotype patient's Clozapine in Treating is 0.008 (being shown in Table 1).COMT gene C DS And the CDS sequence of pleomorphism site is as shown in SEQ ID NO.1；The aminoacid sequence of COMT gene C DS and pleomorphism site thereof Row are as shown in SEQ ID NO.2.
In sum, the present invention is that the relation of research COMT gene pleiomorphism and clinical drug safety is laid a good foundation, for Clinical application individuation is provided fundamental basis, and the most also provides guidance to depend on for new drug development based on pharmacogenomics theory According to.
Above the specific embodiment of the present invention is described.It is to be appreciated that the invention is not limited in above-mentioned Particular implementation, those skilled in the art can make various deformation or amendment within the scope of the claims, this not shadow Ring the flesh and blood of the present invention.
Table 1

Claims (9)

1. the nucleotide containing mononucleotide polymorphism site separated, it is characterised in that the sequence of described nucleotide such as SEQ Shown in ID NO:6, described mononucleotide polymorphism site is positioned at the 20689th, and rs6269 is A → G.
2. a nucleotide as claimed in claim 1 purposes in the test kit of preparation detection Kui sulfur flat medication effect.
3. the nucleotide separated, it is characterised in that the sequence of described nucleotide as shown in SEQ ID NO:6, and the 20689th Position is A.
4. the test kit detecting Kui sulfur flat medication effect, it is characterised in that described test kit includes: according to such as SEQ ID The primer pair of the upstream and downstream design of the 20689th of sequence shown in NO:6.
5. test kit as claimed in claim 4, it is characterised in that described primer pair: SEQ ID No.3, SEQ ID No.4, Shown in SEQ ID No.5.
6. the non-diagnostic purpose using method of the test kit as described in any one of claim 4 or 5, it is characterised in that bag Include following steps:
Step one, extracts sample DNA；
Step 2, utilizes described primer to expand, obtains amplified production；
Step 3, detects the mononucleotide polymorphism site whether existed in described amplified production as shown in SEQ ID NO:6 rs6269。
7. using method as claimed in claim 6, is characterized in that, in step 3, the method for described detection includes: DNA sequencing, Sequencing by hybridization, enzymatic mispairing cutting, heteroduple analysis, dot blot, oligonucleotide arrays, Mini-sequencing, Taqman Technology, molecular beacon or denaturing high-performance liquid chromatography.
8. using method as claimed in claim 6, is characterized in that, in step 2, the actual conditions of described amplification is as follows: reaction System is 20 μ l, wherein contains:
100μmol·L-1DNTPs, 50mmol L-1KCL, 10mmol L-1Tris-HCL (pH8.3), 1.5mmol L-1 MgCl2, 0.5U Taq archaeal dna polymerase, 20-50ng template DNA, 0.5 μ l10pM SEQ ID No.3,0.5 μ l10pM SEQ ID No.4, distilled water complements to 20ul；
PCR reaction condition: 95 DEG C of 2mins；30×(94℃30s；58 DEG C of 30s, 72 DEG C of 30s) 72 DEG C of 5mins.
9. the primer pair being used for detecting the SNP site of nucleotide as claimed in claim 1, it is characterised in that described primer Right: shown in SEQ ID No.3, SEQ ID No.4, SEQ ID No.5.
CN201610298336.XA 2016-05-06 2016-05-06 The test kit of detection Kui sulfur flat medication effect based on rs6269 and using method thereof Pending CN106119244A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610298336.XA CN106119244A (en) 2016-05-06 2016-05-06 The test kit of detection Kui sulfur flat medication effect based on rs6269 and using method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610298336.XA CN106119244A (en) 2016-05-06 2016-05-06 The test kit of detection Kui sulfur flat medication effect based on rs6269 and using method thereof

Publications (1)

Publication Number Publication Date
CN106119244A true CN106119244A (en) 2016-11-16

Family

ID=57270903

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610298336.XA Pending CN106119244A (en) 2016-05-06 2016-05-06 The test kit of detection Kui sulfur flat medication effect based on rs6269 and using method thereof

Country Status (1)

Country Link
CN (1) CN106119244A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109609660A (en) * 2018-12-24 2019-04-12 郑州华之源医学检验实验室有限公司 A kind of individual identification system, detection method and its application
CN109609673A (en) * 2018-12-21 2019-04-12 康美华大基因技术有限公司 A kind of application of bulbus fritillariae cirrhosae ITS1 sequence fragment and the detection method of fritillaria kind

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201350633A (en) * 2012-05-24 2013-12-16 Abbvie Inc Neuronal nicotinic agonists and methods of correlating COMT SNPs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201350633A (en) * 2012-05-24 2013-12-16 Abbvie Inc Neuronal nicotinic agonists and methods of correlating COMT SNPs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GENBANK: "NG_011526.1", 《GENBANK》 *
XU Q，等: "Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population", 《THE PHARMACOGENOMICS JOURNAL》 *
金远香: "CCWT基因多态性与帕金森病易感性及左旋多巴诱导异动症的相关性研究", 《中国优秀硕士论文全文数据库 医药卫生科技辑》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109609673A (en) * 2018-12-21 2019-04-12 康美华大基因技术有限公司 A kind of application of bulbus fritillariae cirrhosae ITS1 sequence fragment and the detection method of fritillaria kind
CN109609660A (en) * 2018-12-24 2019-04-12 郑州华之源医学检验实验室有限公司 A kind of individual identification system, detection method and its application

Similar Documents

Publication Publication Date Title
Urwin et al. Anorexia nervosa (restrictive subtype) is associated with a polymorphism in the novel norepinephrine transporter gene promoter polymorphic region
CN102808026B (en) Primer, probe, fluorescent PCR kit and method for detecting polymorphism of human MTHFR (Methylene Tetrahydrofolate Reductase) gene
CN113046424B (en) Preparation method of nucleic acid composition for PCR detection, nucleic acid composition prepared by preparation method and PCR detection method
JPWO2008117782A1 (en) Gene amplification primer set, gene amplification reagent containing the same, and use thereof
CN112458166A (en) Method for optimizing rheumatoid disease gene SNP locus typing
WO2016165591A1 (en) Mgmt gene promoter methylation detection based on pyrosequencing technology
CN112226505A (en) Respiratory system disease gene SNP locus typing optimization method
CN106119244A (en) The test kit of detection Kui sulfur flat medication effect based on rs6269 and using method thereof
JP5279492B2 (en) Obesity gene amplification primer set, obesity gene amplification reagent containing the same, and use thereof
Hu et al. Genetic analysis of 15 mtDNA SNP loci in Chinese Yi ethnic group using SNaPshot minisequencing
Pichon et al. Analysis and annotation of DNA methylation in two nonhuman primate species using the Infinium Human Methylation 450K and EPIC BeadChips
Moum et al. Mitochondrial control region structure and single site heteroplasmy in the razorbill (Alca torda; Aves)
JP5367365B2 (en) SULT1A1 gene amplification primer set, SULT1A1 gene amplification reagent containing the same, and use thereof
AU2005314732B2 (en) Method for identifying gene with varying expression levels
CN105861685A (en) Kit for testing Quetiapine application effect based on rs5993883 and application method of kit
CN106222268B (en) POU1F1 haplotype molecular marker related to duck growth traits and application
Niederstätter et al. Separate analysis of DYS385a and b versus conventional DYS385 typing: is there forensic relevance?
CN105925679A (en) Kit for detecting medication effects of clozapine and risperidone by virtue of rs4680 polymorphism
Yeetong et al. Pentanucleotide Repeat Insertions in RAI1 Cause Benign Adult Familial Myoclonic Epilepsy Type 8
US20140141432A1 (en) Method and kit for diagnosing glaucoma in dogs
CN110938681A (en) Allele nucleic acid enrichment and detection method
WO2008066161A1 (en) Primer set for amplification of nat2 gene, reagent for amplification of nat2 gene comprising the same, and use of the same
CN107574167B (en) Hyriopsis cumingii microsatellite marker and application thereof
CN104152542B (en) Tumor ABL1 gene loci parting detecting reagent, using method and application
Baek et al. Microarrays for high‐throughput genotyping of MICA alleles using allele‐specific primer extension

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161116